EVE Energy

Phase A — Understand the business

Lens 1 · Company Overview

EVE Energy is a full-spectrum lithium-battery manufacturer built on three legs, in the order they were added:

1. Consumer / lithium-primary batteries — the founding business and the quiet cash engine. Li-SOCl₂ (lithium-thionyl-chloride), Li-MnO₂, ER cells, battery capacitors, small consumer Li-ion and cylindrical cells. EVE is the #1 primary-lithium maker in China for 8 consecutive years by sales and export volume, has shipped >1.9 billion smart-meter batteries, and holds "National Single-Champion Product" status for its Li-SOCl₂ and SPC lines. End-markets: utility metering (water/gas/electric smart meters), IoT, ETC/telematics, medical devices, industrial monitoring — long-shelf-life, high-reliability niches.
2. Power batteries (EV) — entered 2015. Prismatic LFP, prismatic/pouch NCM, and the 46-series large cylindrical platform (46mm-diameter, full-tab). The marquee win is BMW's Neue Klasse (model G16 INR4695E), a >€10bn multi-year cell contract.
3. Energy-storage systems (ESS) — entered alongside power in 2015, now the growth spearhead. Large-format LFP cells (280Ah / 306Ah / the 628Ah "Mr. Big"), full BESS systems up to 6.9MWh. Global top-3 in ESS cell shipments since 2023.

Founded 2001 (Huizhou, Guangdong), listed on Shenzhen GEM/ChiNext in 2009. Founder-led (Dr. Liu Jincheng, chairman & GM).

Contract structure: a mix. ESS runs on multi-year Master Supply Agreements (e.g. Powin 15GWh MSA covering 280/306Ah LFP cells; Tesla ESS cells from Malaysia from 2026) — volume commitments, not take-or-pay, priced off a moving lithium/cell benchmark. EV is program-locked (BMW multi-year). Primary-lithium is book-of-business industrial supply. Revenue is cell/system unit sales, not recurring — so the model is fundamentally volume × spread, and the spread is set by an over-supplied cell market (see Lens 5/13).

Customers named: BMW (EV, Neue Klasse), Tesla (ESS cells, from 2026, "sixth battery supplier / third ESS supplier"), Powin (US ESS, 15GWh MSA), plus India ESS (8GWh order, 60GWh tie-up in discussion). Commercial-vehicle installations rank #2 in China.

Lens 2 · Supply Chain

Upstream → EVE → end-customer, named nodes:

Upstream (materials):

• Lithium carbonate / hydroxide — market-priced (SMM benchmark, ~RMB 169k/t as of Jun 2026 ). EVE took a 20% stake in Shandong Ruifu Lithium (lithium carbonate/hydroxide producer) for part of a RMB 800m Sept-2022 upstream package.
• Anode / negative-electrode material — 40% stake in BTR Sichuan New Material (subsidiary of BTR New Material Group, the world's largest anode maker) — same RMB 800m package. This is a vertical-integration tell: EVE co-owns its anode supply.
• Cathode (LFP / NCM), separators, electrolyte, copper/aluminium foil — sourced from China's deep battery-materials ecosystem; specific counterparties not disclosed in web sources (n/a). China's LFP and separator supply is structurally abundant, which is good for EVE's input cost and bad for its output pricing (everyone else has the same cheap inputs).
• Equipment / greenfield build — MoU with ABB to support sustainable greenfield battery manufacturing globally; Fujian Longking as JV partner on the 60GWh Shanghang plant.

Midstream (EVE manufacturing):

• Domestic bases: Huizhou, Hubei (Jingmen), Jiangsu, Sichuan, Yunnan, Zhejiang.
• International: Malaysia (48GWh across two phases; phase-1 done Feb 2025 at ~US$420m; phase-2 deliveries Q1 2026); Hungary (Debrecen, ~28–30GWh, €1bn, 46-series NMC for BMW, mass-production 2027); US (~21GWh prismatic LFP, ~US$2.64bn, 2027); Indonesia in development.

Downstream (buyers): automakers (BMW, commercial-vehicle OEMs), ESS integrators (Powin, Tesla, Indian developers), smart-meter/IoT OEMs.

Chokepoints & single-source dependencies:

• Lithium price is the single biggest swing factor — not a supplier lock but a margin lever EVE only partly hedges via its Ruifu stake.
• BMW Hungary program concentrates a large EV bet on one customer + one geography + one unproven-at-scale 46mm format; a BMW volume slip or Neue Klasse EV-demand miss hits a purpose-built plant (see Lens 13).
• Overseas (Malaysia) as the "China+1" tariff bypass for US-bound Tesla ESS cells is a genuine strategic node — but also a policy-exposed one (US IRA/tariff regime on Chinese-owned cell capacity).

Names present → this lens holds. The gap is materials-tier counterparties (electrolyte/separator), which web sourcing doesn't expose.

Lens 3 · Competitive Advantages (moats)

Where the moat is real:

• Lithium-primary franchise — this is the genuinely durable moat. #1 in China for 8 years, National Single-Champion, 1.9bn smart-meter cells. Li-SOCl₂ for metering/IoT is a high-reliability, spec-locked, 10-20yr-shelf-life niche where qualification cycles are long and the switching cost is real. Global competition is thin (Saft, Tadiran/Tenergy, EVE) — this is a pricing-power pocket inside an otherwise commoditised company. It doesn't move the top-line needle much anymore, but it's the reason EVE is cash-generative through a cell price war.
• Scale + cost position in ESS — top-3 global ESS shipper (150GWh cumulative by Dec 2025) buys learning-curve and procurement scale. Large-format leadership (628Ah "Mr. Big", 6.9MWh system) is a genuine engineering lead — but a transient one; format leadership in Chinese batteries has a ~12-18 month half-life before peers copy it.
• 46-series large cylindrical + BMW anchor — being one of only two BMW Neue Klasse cell suppliers (alongside CATL) is a credential moat and a Western-OEM foot-in-door that most Chinese peers lack. If 46mm becomes the premium-EV standard, EVE is early.
• Vertical integration into anode (BTR Sichuan 40%) and lithium (Ruifu 20%) — a modest structural cost edge.

Where the moat is weak (the honest read):

• EVE is a #5-6 global / ~2.6% EV-share player competing below CATL (38%) and BYD (17%). It is a scale-taker, not a scale-setter — it does not set the industry price; CATL does.
• Cells are commoditising fast — BNEF pack prices hit ~US$108/kWh (2025), stationary-storage tenders in China as low as US$63/kWh. In a business where the product is converging on a spec-sheet commodity, "moat" is really cost-per-kWh rank + balance-sheet endurance, and on both EVE is second-tier to CATL/BYD.

Bargaining power: Weak over customers (Tesla/BMW/Powin are large, multi-sourced, and hold the whip on price), moderate over suppliers (partly self-owned upstream; buys in an over-supplied materials market). Who needs whom more? For ESS/EV, EVE needs the customer more than the customer needs EVE — that is the core competitive vulnerability. Only in primary-lithium does the balance flip in EVE's favour.

Lens 4 · Segments

FY2025 revenue = RMB 61.47bn (+26.44% YoY).

• ESS is now the second-largest revenue line and the fastest-growing by shipment; it overtook power batteries in shipments in Q1 2026 for the first time (ESS 20.38GWh vs power 14.34GWh). Cumulative global ESS shipments crossed 150GWh by Dec 2025.
• Power (EV) grew shipments +65.56% and expanded gross margin to 15.50% (+1.3pp) — the one segment where EVE gained both volume and margin, driven by commercial-vehicle installs (#2 in China) and the ramp toward 46mm/BMW.
• Consumer/primary — web sources did not break out FY25 consumer revenue or margin (n/a for the exact figure); it is the residual inside the ~RMB 37bn power+consumer bucket. Directionally it is the highest-margin, slowest-growth leg (see Lens 3).
• Geography — domestic (6 Chinese bases) still dominant; overseas revenue share not disclosed in web sources (n/a). The overseas capacity build (Malaysia/Hungary/US) is running ahead of overseas revenue, which is the crux of the capex-vs-utilisation tension (Lens 10/13).

Trend & cause: the mix is rotating from power toward ESS, and ESS is the lower-margin of the two — so the segment shift is top-line-accretive but margin-dilutive at the gross level, exactly the "revenue up, profit flat" signature seen in FY25 (see Lens 5). Margin recovery therefore depends less on mix and more on the cell-price cycle turning (Lens 5/8).

---

Phase B — Measure performance

Lens 5 · Earnings Result

Latest full-year print — FY2025:

• Revenue RMB 61.47bn, +26.44% YoY (vs RMB 48.61bn FY24). Record high.
• Net profit attributable RMB 4.134bn, +1.44% YoY — essentially flat despite +26% revenue. This is the headline tension.
• Ex-equity-incentive net profit RMB 5.002bn, +24.76% YoY — i.e. an ~RMB 868m equity-incentive expense suppressed reported GAAP profit. Adjusted for it, profit grew roughly in line with revenue.
• Power GM 15.50% (+1.3pp); ESS GM 12.28% (−2.44pp) — margins bifurcated: EV up, storage down under price pressure.
• Market position: #6 global power-battery shipments per EVTank; #2 China commercial-vehicle installs; #5-8 global cell maker (~2.6% EV share) per Benchmark/SNE.

The 60GWh announcement shipped with the FY25 results (a new 60GWh power project) — management pairing a flat-profit print with a big capacity signal, which the market read as confidence but which also deepens the overbuild (Lens 10).

Most recent quarter — Q1 2026:

• Revenue RMB 20.68bn, +61.61% YoY — record for the period.
• Net profit attributable RMB 1.446bn, +31.35% YoY; ex-non-recurring RMB 1.115bn, +36.32%.
• ESS shipments (20.38GWh) overtook power (14.34GWh) for the first time — the inflection.
• Announced RMB 11bn of new plants (50GWh Jiangsu + 60GWh Fujian Longking JV) the same day.

Guidance — H1 2026 (issued 15 Jun 2026):

• Net profit attributable RMB 3.13–3.37bn, +95% to +110% YoY.
• Ex-non-recurring RMB 2.43–2.60bn, +110% to +125%.
• Revenue ~+60% YoY. Implied Q2 net profit RMB 1.68–1.93bn (+16-33% QoQ).
• Cause cited: product iteration, process optimisation, "successfully mitigated rising supply-chain pressures" (i.e. passed through the lithium repricing).

Balance-sheet flags: the concern isn't the P&L, it's the funding of it — interest-bearing debt RMB 31.5bn (Jun 2025), D/E 76.73%, construction-in-progress RMB 12.27bn (H1 2025, up from RMB 9.31bn end-2024), RMB 5.14bn convertible bonds. See Lens 10.

Read: the tape flipped from flat (FY25) to inflecting hard (Q1'26 → H1'26 guide). The driver is spread recovery (lithium up, anti-involution ending the price war, tax-rebate rollback) far more than a structural margin improvement — a cyclical earnings turn, correctly identified as the near-term thesis.

Lens 6 · Earnings Calls (sentiment trend)

No transcripts on the research-layer shelf (A-share names don't produce EDGAR-indexed English earnings calls; transcripts=0). Substituting management's public commentary and results-briefing tone across the last ~4 reporting points:

• Q3 2024 / FY2024 (trough): defensive tone. Chairman Liu had publicly warned of industry-wide overcapacity "by 2024 at the latest," with only high-quality/low-cost product spared. FY24 was flat (rev −0.3%, profit +0.6%) — management framing was survival-and-share-gain, not growth.
• H1 2025 (pressure): revenue +30% but net profit −24.9% YoY; commentary acknowledged falling capacity utilisation and margin compression while defending the debt-funded expansion. This is the low-confidence point in the arc.
• FY2025 (turn signalled): tone shifts to scale-leadership and product-definition — "large cylindrical and large-storage products defining industry benchmarks"; paired flat GAAP profit with the 60GWh announcement.
• Q1 2026 → H1 2026 guide (confident): the language is now growth + margin recovery + supply-chain pass-through mastery; the +95-110% H1 guide is the loudest possible tone shift.

Recurring phrases: "globalisation strategy," "large cylindrical / large storage," "product iteration," "cost leadership." What they stopped saying: the 2023-24 overcapacity/utilisation anxiety — by mid-2026 the framing is offensive, not defensive. Sentiment trajectory: defensive (FY24) → strained (H1'25) → confident (H1'26) — a textbook cyclical-bottom-to-recovery arc, which validates the earnings-turn read but also warns that today's tone is peak-optimism relative to a still-oversupplied industry.

Lens 7 · Comps

Peer set = global lithium-cell makers (index + obvious names). Multiples are with source/date, or `n/a`. USD market caps at ~7.2 RMB/USD, ~1,360 KRW/USD, ~155 JPY/USD, ~7.8 HKD/USD are.

• 5-yr average ROE: n/a for the full peer row (web didn't return clean 5yr-avg ROE by name). EVE TTM ROI ~9.51%; profit margin 6.46% TTM. CATL's returns are structurally higher (10bn-USD net profit, premium margins).

Read: EVE trades at ~30x TTM P/E — a premium to CATL (~22x) and LGES (~10-18x), despite materially thinner margins and lower returns than CATL. That premium is the market pre-paying for the H1'26 profit-doubling and the ESS/46mm growth optionality. On trailing fundamentals EVE looks expensive vs CATL; on forward (post-doubling) earnings the multiple compresses meaningfully (Lens 11). The valuation only works if the earnings turn is real and durable — which is precisely the bet.

Lens 8 · Stock-Price Catalysts

Moves >5% and what they reveal (mostly ``; A-share daily limit is ±20% for ChiNext, so single-day swings can be large):

• 2021–late-2022 — lithium spike to ~US$50k/t + EV/ESS demand boom: shares rode the up-cycle; EVE's ESS breakout to global top-3 (2023) was rewarded.
• 2023–2024 — lithium collapse (~−90% from 2022 peak) + overcapacity price war: de-rating. FY24 flat results; the stock's 52-week range (RMB 41.52–94.44) captures the volatility. The market reacts hardest to the lithium price and the cell-price war — this is a macro/commodity-beta name as much as a company story.
• Dec 2024 — Tesla ESS supply agreement revealed: a positive customer-name catalyst (Tesla's 6th battery supplier).
• 2025 — H1 profit −24.9%, utilisation falling: negative; the debt-funded-expansion anxiety.
• Nov 2025 — MIIT anti-involution campaign (12 battery firms summoned) + lithium recovery begins: sector-wide positive re-rate signal.
• Apr 2026 — Q1 +31% profit + RMB 11bn expansion + ESS overtakes power: stock surged ("why is EVE surging today").
• 15 Jun 2026 — H1 guide +95-110%: the biggest fundamental catalyst; explains the run toward RMB 64-65.
• 2 Jan 2026 — HKEX H-share re-filing (CITIC sole sponsor): structural catalyst — an A+H dual listing to fund Hungary; adds an overhang-vs-liquidity dynamic.

Pattern: EVE's tape is driven, in order, by (1) the lithium/cell-price cycle, (2) marquee customer wins (Tesla/BMW), (3) quarterly profit-growth surprises, (4) capacity/policy events. It is a cyclical + thematic stock — it reacts to the industry spread more than to idiosyncratic EVE execution. That makes the current setup (spread recovering + profit doubling) the sweet spot, and the next down-leg in cell prices the primary risk.

---

Phase C — Judge people & books

Lens 9 · Management

• Dr. Liu Jincheng — Co-founder, Chairman & General Manager. Hubei-born, worked at a state-owned factory post-college, studied electrochemistry at Wuhan University, battery engineer before founding EVE in 2001. A technical founder-operator who built EVE from a primary-lithium specialist into a top-6 global cell maker across 24 years — a quantifiable, multi-decade track record. Forbes-listed billionaire ("Liu Jincheng & family").
• Ms. Luo Jinhong — Co-founder & Controller. Liu's spouse; the classic Chinese founder-couple control structure.
• Skin in the game / ownership: post the Nov-2022 A-share placement, the controlling bloc = EVE Holdings 32.08% + Liu 3.79% + Luo 4.05% ≈ 40%. High founder alignment — a positive.
• Capital-allocation history — mixed-to-aggressive. The signature move is relentless, debt-funded capacity expansion (84GWh end-2023 → 112.9GWh end-2024 → ~210GWh planned; +RMB 11bn announced Q1'26). On the smart side: early, non-consensus vertical integration (BTR anode 40%, Ruifu lithium 20%) and the opportunistic Smoore International play — EVE bought 50.1% of Smoore (vaping/Feelm) for RMB 440m in 2014, which IPO'd in HK in 2020; EVE still holds ~30.73% and is methodically reducing it (authorised to trim up to 3.5% / ~216.6m shares) to recycle capital into batteries. That Smoore stake is one of the great venture returns in Chinese industrials and has quietly funded the battery build. On the risky side: the 2x capacity overbuild into a price war, and share pledges (below).
• Red flags: ~13.92% of total shares pledged by the controlling shareholders to PRC financial institutions (EVE Holdings 270.5m, Liu 18.2m shares) as financing collateral — a common-in-China but genuine margin-call/control risk if the stock falls sharply. Equity-incentive expense (~RMB 868m in FY25) is large enough to swing reported profit — legitimate but worth watching for repeat non-GAAP flattering. No related-party accounting scandals surfaced (Lens 10).
• Archetype: founder-technologist, not professional caretaker — implies high conviction, fast capacity bets, and a builder's tolerance for leverage. For a company trying to out-endure a price war, founder control is an asset; the leverage is the price of that conviction.

Lens 10 · Forensic Red Flags

Forensic read, all figures `` (no primary filings on shelf).

Balance sheet — the primary risk cluster:

• Interest-bearing debt RMB 31.5bn; D/E 76.73% (Jun 2025) — high and rising, funding capacity ahead of demand.
• Construction-in-progress RMB 12.27bn (H1 2025, up from RMB 9.31bn end-2024) — a large, non-earning asset base. CIP that outruns revenue is the classic "capex-ahead-of-utilisation" flag; capacity utilisation was explicitly falling in H1 2025.
• Convertible bonds RMB 5.14bn (RMB 4.97bn net raised Mar 2025) — dilution overhang + refinancing dependence.
• ~2x capacity overbuild (112.9GWh end-2024 vs ~210GWh planned) — the structural asymmetry: if ESS/EV demand or pricing disappoints, EVE carries depreciation and interest on idle lines.

Income statement:

• Reported vs adjusted profit gap: FY25 GAAP RMB 4.134bn vs ex-incentive RMB 5.002bn — the ~RMB 868m equity-incentive expense materially shapes the headline. Not a manipulation, but it means "reported EPS" and "underlying EPS" diverge by ~20%; be explicit about which is used.
• Non-recurring items: Q1'26 GAAP RMB 1.446bn vs ex-non-recurring RMB 1.115bn — a ~RMB 331m non-recurring gain. A recurring feature of EVE's P&L is investment income / fair-value swings from the Smoore stake (a listed HK holding marked to market) — this can flatter or hit reported profit independent of the battery business. Watch the Smoore mark as a profit-quality issue, especially as EVE sells down.
• Segment margin honesty: ESS GM fell to 12.28% while revenue rose — no evidence of margin-masking; disclosure appears consistent with the price-war narrative.

Cash flow vs earnings: web sources don't give a clean FCF/CFO bridge (n/a), but the combination of rising debt + rising CIP + flat profit strongly implies negative-to-thin free cash flow during the build — the expansion is funded by debt + converts + the Smoore selldown, not by operating cash. This is the single most important thing a future refresh should quantify from the annual report/prospectus.

Regulatory findings (required sub-section):

• SEC (EDGAR LR + AAER): None possible — EVE has no CIK and is not an SEC filer; regulatory/regulatory-findings.md (fetched 2026-07-06) confirms 0 SEC findings and notes the search cannot run.
• Non-SEC / web: a targeted search for "EVE Energy" (FTC OR DOJ OR consent decree OR settlement OR fine OR penalty) enforcement surfaced no material enforcement actions, consent decrees, or fines against EVE Energy in the reviewed results (as of 2026-07-06). Note: several unrelated entities share the "EVE"/"EV Energy" name in SEC results (Eve Holding Inc / eVTOL; EV Energy Partners) — none are this company.
• China-domestic / CSRC: no CSRC enforcement or exchange-censure surfaced in web sources (n/a — not exhaustively verifiable via web; a Chinese-language CSRC/SZSE check is the gap a future refresh should close).
• Item 3 (Legal Proceedings): not available — no 10-K exists (n/a — no filing). The HKEX prospectus, once effective, will carry the equivalent litigation disclosure and should be read directly.
• Net: No material regulatory or legal findings identified — verified via SEC EDGAR EFTS (LR/AAER, structurally N/A), web enforcement search, and the absence of any 10-K, as of 2026-07-06. This is a "not found," not a clean audited "none" — the web-only ceiling applies.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection

All figures `` built bottom-up from FY25 actuals + H1'26 guidance. Currency RMB. EVE has ~2.17bn shares; FY25 GAAP EPS ≈ RMB 4.134bn / 2.17bn ≈ RMB 1.90. Fiscal year = calendar year.

Anchor: FY25 GAAP net profit RMB 4.134bn (RMB 5.002bn ex-incentive). H1'26 guided RMB 3.13–3.37bn (+95-110%). If H1 = RMB 3.25bn (midpoint) and H2 runs at a similar-or-better spread (lithium firm, price war easing), full-year FY26 net profit ≈ RMB 6.3–7.0bn.

Implied valuation: at RMB ~64.6 / ~2.17bn shares → ~RMB 140bn cap, base-case FY26 EPS ~RMB 3.04 puts EVE at ~21x FY26E and ~18x FY27E — i.e. the ~30x trailing multiple compresses to low-20s/high-teens forward if the doubling lands. The stock is not expensive on forward earnings; it is expensive only if the earnings turn is a head-fake. That is the entire debate.

Brier forecast (base call): not logged in --watchlist mode per skill rules (no forecast.ts create in the unattended loop). The base-case scoreable claim, for a future manual log, would be: "300014.SZ FY26 GAAP net profit ≥ RMB 6.3bn", p≈0.60, resolves 2027-03-31.

Lens 12 · Bull vs Bear

Bull case. EVE is a cyclical earnings-doubling story wrapped around a real structural franchise. Three engines fire at once: (1) the cell-price cycle has turned — lithium carbonate back to a 2-year high (~RMB 169k/t), China's anti-involution campaign ending the destructive price war, and the tax-rebate rollback all restoring spread; H1'26 profit is guided +95-110%. (2) ESS is a secular megatrend (global BESS +51% to 315GWh in 2025, 450GWh forecast 2026) and EVE is top-3 globally with format leadership (628Ah, 6.9MWh) and blue-chip customers (Tesla, Powin). (3) Optionality stacks up: BMW Neue Klasse 46mm (>€10bn), a solid-state roadmap (350Wh/kg ASSB 2026, >1000Wh/L 2028), the Malaysia "China+1" tariff bypass, and a HK H-share listing to fund Hungary and de-lever. The genuinely durable primary-lithium franchise (global #1, National Single-Champion, spec-locked metering/IoT) provides a cash-generative floor that pure-play cell makers lack. On forward earnings (~21x FY26E) the premium multiple is reasonable.

Bear case (permanent-impairment risks). (1) The balance sheet is levered into a ~2x capacity overbuild — RMB 31.5bn debt, D/E 77%, RMB 12.3bn of non-earning CIP, into an industry with 3TWh capacity vs ~1TWh demand. If the spread recovery is a head-fake and cell prices re-soften, EVE carries interest + depreciation on idle lines and the equity gets squeezed — this is the scenario that permanently impairs returns, not just a bad quarter. (2) EVE is a price-taker, not a price-setter — #5-6 global, ~2.6% EV share, below CATL (38%) and BYD (17%); in a commoditising cell market it competes on cost rank and endurance, and on both it is second-tier to CATL. (3) Customer concentration in ESS/EV — Tesla/BMW/Powin hold the pricing whip and are multi-sourced; a BMW Neue-Klasse volume miss strands a purpose-built Hungary plant. Expectations baked in: ~30x trailing P/E prices the doubling as near-certain.

Pre-mortem (18 months out, thesis broke). It's early 2028. The 2026 profit-doubling was real but proved to be peak-cycle — anti-involution enforcement lapsed, a fresh wave of Chinese ESS capacity (EVE's own included) re-flooded the market, cell prices fell back to 2025 lows, and ESS gross margin slid below 10%. The Hungary and US plants came online into soft Western EV demand and ran at 40-50% utilisation, so depreciation + interest turned the incremental capacity cash-negative. The Smoore stake, sold down to fund the build, no longer cushions the P&L. The stock round-tripped from RMB 65 to the low-40s (its prior 52-week floor). The tell we'd have wanted: watch H2'26 cell-price tenders and utilisation — if tenders stay sub-US$70/kWh and utilisation doesn't recover above ~75%, the doubling is a spread-timing artifact, not a durable re-rating.

Multiples too high? On trailing yes (30x vs CATL 22x with worse margins); on forward base-case no (~21x FY26E). The multiple is a cycle-timing bet, not a structural over/under-valuation.

Contrarian view (what the market is refusing to see). The bull crowd is fixated on the ESS growth number and the +110% profit guide; the bear crowd is fixated on the debt. What both are underweighting is the primary-lithium franchise — a genuinely moated, high-margin, spec-locked cash business (global #1, 1.9bn smart-meter cells) that gets zero narrative credit because it doesn't grow fast. It is the reason EVE survived the price war profitably when weaker peers bled, and it's an under-appreciated downside cushion. The market treats EVE as a levered ESS/EV beta play; the hidden truth is there's a Saft-like specialty-battery business inside it that never shows up in the pitch.

Lens 13 · Devil's Advocate (short-seller)

Skeptical short thesis.

• What structurally breaks the model: EVE sells a commoditising unit (a kWh of LFP) into a structurally oversupplied market it doesn't control (3TWh capacity / ~1TWh demand), funded by debt and dilution. The entire margin recovery is spread, not skill — set by the lithium price and Beijing's willingness to enforce anti-involution, both exogenous. When (not if) the next capacity wave or lithium down-leg hits, EVE has no pricing power (price-taker at #5-6) and a fixed-cost + interest base sized for 210GWh. That is operating + financial leverage into a cyclical commodity — the short's dream setup on any spread reversal.
• Revenue concentration: ESS is now ~40% of revenue and rotating higher — the lowest-margin segment, dependent on a handful of large, multi-sourced integrators (Tesla, Powin) who will re-tender aggressively. EV is anchored to one Western program (BMW Neue Klasse) whose volume depends on European premium-EV demand that has repeatedly disappointed. If Neue Klasse EV uptake is soft, the €1bn Hungary plant is a stranded, purpose-built asset.
• Moat weaker than bulls think: format leadership (628Ah, 46mm) has a 12-18 month copy half-life in Chinese batteries; CATL and BYD out-scale, out-spend R&D (CATL ~US$2.6bn vs EVE far less), and out-cost EVE. The "moat" outside primary-lithium is really just current cost rank, and it's not #1.
• Worst capital-allocation moves: 2x capacity overbuild into a declared price war; ~13.92% of shares pledged by controllers (a stock-drop → margin-call → forced-selling reflexive risk); reliance on Smoore mark-to-market gains to smooth reported profit; issuing converts (dilution) at the same time as running a big equity-incentive expense that flatters non-GAAP.
• Assumptions that must hold for RMB ~65: (a) H1'26 spread persists through H2 and into 2027; (b) overseas plants (Malaysia/Hungary/US) ramp near-on-time at healthy utilisation; (c) no fresh Chinese ESS oversupply crushes cell prices again; (d) lithium stays firm. Break any one and the ~30x trailing multiple has nothing under it.
• If growth disappoints 20-30%: base-case FY26 profit RMB 6.6bn → ~RMB 4.6-5.3bn, EPS ~RMB 2.1-2.4, and the multiple you're paying on the disappointed number is ~27-31x — with a stretched balance sheet underneath. Downside to the prior 52-week floor (~RMB 41) is ~35%.
• Single permanently-impairing scenario: a synchronized H2'26/2027 cell-price relapse + Western-EV demand miss that leaves the overseas capacity idle and cash-negative while debt service is fixed — plausibility moderate (it's literally the pattern of 2023-24, one cycle ago). Most-dangerous competitor bulls underestimate: BYD (in-house cells + vertical integration + its own ESS push) as much as CATL — BYD can price ESS/EV cells at a level EVE structurally cannot match.

Lens 14 · Management Questions (ordered by information value)

1. Your H1'26 profit is guided +95-110% — how much of that is durable spread vs a 2-3 quarter lithium-price/anti-involution timing effect? What's your assumed cell price and lithium carbonate cost for H2'26 and 2027?
2. You have ~2x capacity under construction/planned vs current output. What blended utilisation do Malaysia, Hungary, and the US plants need to be cash-flow-positive, and what utilisation are you actually underwriting for 2027?
3. Walk through the free-cash-flow bridge for FY25 and H1'26 — how much of the capex was funded by operating cash vs debt vs converts vs the Smoore selldown?
4. At RMB 31.5bn interest-bearing debt and 77% D/E, what is your target leverage, and does the HK H-share raise fully fund Hungary or do you need further debt/converts?
5. The controlling shareholders have pledged ~13.9% of shares. At what stock price do those pledges risk margin calls, and what's the plan to de-pledge?
6. How much of the Smoore stake remains monetisable, and how should we model the investment-income/fair-value contribution to reported profit going forward — i.e. what's "core battery" profit ex-Smoore?
7. BMW Neue Klasse is your Western EV anchor. What are your contracted minimum volumes, and what happens to Hungary's economics if Neue Klasse EV demand runs 30% below plan?
8. In ESS — your fastest-growing but lowest-margin line — what's the path to structurally higher gross margin beyond the current spread tailwind? Is it format (628Ah), integration, or overseas premium?
9. Where do you have genuine, durable pricing power vs CATL and BYD, segment by segment — and where are you honestly a price-taker?
10. On solid-state: the roadmap is 350Wh/kg ASSB in 2026 and >1000Wh/L in 2028. What's the realistic commercial-volume timeline and capex, and how do you avoid stranding today's liquid-electrolyte capacity?
11. The primary-lithium business is your most-moated, highest-margin franchise but gets little external credit. What are its revenue, margin, and growth, and why not spotlight it more?
12. US policy risk: your US plant and Malaysia-to-US ESS flow depend on the tariff/IRA regime. How exposed is that revenue to a tightening of rules on Chinese-owned cell capacity?
13. Chinese anti-involution guidance discourages "irrational" overseas expansion and price wars. How does your ~230GWh expansion plan reconcile with that policy direction?
14. The ~RMB 868m FY25 equity-incentive expense swings reported vs adjusted profit ~20%. What's the multi-year cadence of that expense, and how should we think about GAAP vs non-GAAP EPS?
15. If cell prices relapse to 2025 lows in H2'26, what is your defensive playbook — pause capex, cut the expansion, or push volume to defend share?

---